Infliximab Therapy and the Central Nervous Demyelination in Patients with Kawasaki Disease
We performed brain magnetic resonance imaging in 14 patients with Kawasaki disease who were treated with infliximab (IFX) at 56 months of age (32–62 months of age) and 23 months (5–35 months) after IFX therapy. Magnetic resonance imaging showed no finding of the central nervous demyelination. IFX therapy is not related to central nervous demyelination in patients with Kawasaki disease.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Brief Reports Source Type: research
More News: Brain | Infectious Diseases | Kawasaki Disease | MRI Scan | Neurology | Pediatrics | Remicade